The ABSCF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABSCF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ABSCF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ABSCF Detailed Price Forecast - CNN Money||View ABSCF Detailed Summary - Google Finance|
|View ABSCF Detailed Summary - Yahoo! Finance||View ABSCF Stock Research & Analysis - Zacks.com|
|View ABSCF Trends & Analysis - Trade-Ideas||View ABSCF Major Holders - Barrons|
|View ABSCF Call Transcripts - NASDAQ||View ABSCF Breaking News & Analysis - Seeking Alpha|
|View ABSCF Annual Report - CompanySpotlight.com||View ABSCF OTC Short Report - OTCShortReport.com|
|View ABSCF Fundamentals - TradeKing||View ABSCF SEC Filings - Bar Chart|
|View Historical Prices for ABSCF - The WSJ||View Performance/Total Return for ABSCF - Morningstar|
|View the Analyst Estimates for ABSCF - MarketWatch||View the Earnings History for ABSCF - CNBC|
|View the ABSCF Earnings - StockMarketWatch||View ABSCF Buy or Sell Recommendations - MacroAxis|
|View the ABSCF Bullish Patterns - American Bulls||View ABSCF Short Pain Metrics - ShortPainBot.com|
|View ABSCF Stock Mentions - StockTwits||View ABSCF Stock Mentions - PennyStockTweets|
|View ABSCF Stock Mentions - Twitter||View ABSCF Investment Forum News - Investor Hub|
|View ABSCF Stock Mentions - Yahoo! Message Board||View ABSCF Stock Mentions - Seeking Alpha|
|View Insider Transactions for ABSCF - SECform4.com||View Insider Transactions for ABSCF - Insider Cow|
|View ABSCF Major Holdings Summary - CNBC||View Insider Disclosure for ABSCF - OTC Markets|
|View Insider Transactions for ABSCF - Yahoo! Finance||View Institutional Holdings for ABSCF - NASDAQ|
|View ABSCF Stock Insight & Charts - FinViz.com||View ABSCF Investment Charts - StockCharts.com|
|View ABSCF Stock Overview & Charts - BarChart||View ABSCF User Generated Charts - Trading View|
AB Science provides an update on the restructuring of its clinical development department in 2018
Posted on Wednesday December 19, 2018
FR0010557264 - AB), a pharmaceutical company specialized in the research and development of protein kinase inhibitors (PKIs), has completed reorganization of its clinical development activity to ensure compliance with good clinical practices as a consequence of the ANSM decision to put AB Science studies on clinical hold in France. AB Science provides here the main achievements of this restructuring.
AB Science announces that the masitinib phase 3 study in Alzheimer's disease has completed patient recruitment
Posted on Monday October 22, 2018
FR0010557264 - AB), a pharmaceutical company specialized in the research, development and marketing of protein kinase inhibitors (PKIs), announces today that the masitinib phase 3 study in Alzheimer`s disease has completed patient recruitment.
What Are The Drivers Of AB Science SA’s (EPA:AB) Risks?
Posted on Friday September 14, 2018
Anyone researching AB Science SA (EPA:AB) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory.Read More...
AB Science reports positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancer
Posted on Monday July 23, 2018
FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces the positive recommendation of the Independent Data Monitoring Committee (IDMC) to continue, based on the planned trend-analysis, the study AB12010 in the third and fourth-line treatment of metastatic colorectal cancer. Study AB12010 is an open-label, randomized, adaptive phase 2/3 study comparing the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid), versus Best Supportive Care in third or fourth line of treatment of patients with metastatic colorectal cancer.